Compare Beyond Meat Inc (BYND) vs Centene Corp (CNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Centene Corp — how do they compare? Beyond Meat Inc trades at $0.4 (market cap $215.41M), while Centene Corp trades at $66.97 (market cap $32.05B). The key difference: Centene Corp is far larger — about 148.8× Beyond Meat Inc's market cap, and Centene Corp is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| BYND | CNC | |
|---|---|---|
Market Cap | $215.41M | $32.05B |
Sector | Consumer Staples | Health |
52-Week High | $3.62 | $68.72 |
52-Week Low | $0.42 | $26.17 |
Enterprise Value | $455.69M | $21.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Beyond Meat (BYND) trades at $0.52, down 3.29% amid bearish technical signals and recent reverse stock split. The company shows mixed fundamentals with revenue declining from $419M in 2022 to $275M in 2025, though net income turned positive at $178M in 2025 with a 64.6% margin. Technical indicators show bearish momentum with moving averages signaling sell and ADX confirming strong downtrend, while RSI remains neutral. Recent news highlights stock collapse to all-time lows following the 30:1 reverse split announcement in August 2026.
Investment outlook remains highly risky with 57% analyst sell ratings and persistent cash burn from operations. While valuation ratios appear attractive (P/S 0.61, EV/EBITDA 1.28), declining revenue and negative operating cash flow (-$145M in 2025) challenge sustainability. The turnaround strategy focusing on international expansion faces execution risks amid competitive pressures and consumer demand uncertainties.
Centene (CNC) trades at $66.56, up 1.2% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $71.00. The company reported strong Q2 2026 earnings of $2.51 per share, beating estimates, and raised its full-year EPS guidance, reflecting margin recovery and cost discipline. Revenue growth remains robust, projected to reach $202.9 billion in 2026, though net income margins are negative due to elevated medical costs.
The stock presents a value opportunity with low P/E (8.06) and P/S (0.16) ratios, but investors face risks from Medicaid membership volatility and regulatory pressures. Analyst sentiment is strongly bullish (61% buy ratings), with institutional interest growing, as seen in recent fund additions. Near-term upside is likely if cost controls sustain profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →
